Trial reportNeuropsychiatric disease and treatment2025
Reliability and Validity of the Chinese Version of the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) in Patients with Major Depressive Disorder-a Cross-Cultural Adaptation Study.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Assessing adverse medication reactions can play a vital role in maximizing therapeutic outcomes by promoting the adherence and minimizing the cost of medication therapy in patients with major depressive disorder (MDD). Selecting a simple clinical tool that helps physicians assess and treat patients more effectively is necessary. The Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale has already been proven to be an effective measurement. This study aimed to identify the reliability and validity of the Chinese version of the FIBSER in MDD. Methods: Patients who had been diagnosed with MDD according to the Diagnostic and Statistical Manual for Mental Disorders - Fifth Edition (DSM-5) were enrolled (n=105). The depressive symptoms and adverse medication reactions were assessed by using the Hamilton Depression Scale (HAMD), the Treatment Emergent Symptom Scale (TESS), and the Frequency, Intensity, and Burden of Side Effects Rating Scale (FIBSER). The psychometric analysis was conducted on the FIBSER. Results: The Cronbach's α coefficient for the FIBSER in patients with MDD ranged from 0.872 to 0.942. After four weeks, the test-retest reliability was evaluated with the intraclass correlation coefficient (ICC) ranging from 0.335 to 0.456. The parallel validity of the FIBSER was examined using Pearson's correlation analysis, and r values ranged from 0.694 to 0.776 (P<0.001), which indicated significantly moderate to high correlations between FIBSER and TESS. Conclusion: The Chinese Version of the FIBSER demonstrates acceptable validity and internal consistency reliability, though test-retest reliability was low in this sample of major depressive disorder patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.